Er OON denied for failing step therapy by UnitedHealthcare?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What UnitedHealthcare typically requires
UnitedHealthcare's specific coverage criteria for er oon are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The UnitedHealthcare angle on Er OON
## Why UnitedHealthcare Requires Step Therapy for Extended-Release Opioids
UnitedHealthcare's step-therapy (also called "fail-first") requirement for extended-release opioids means the plan expects documentation that the patient has first tried one or more specified prior-step therapies — typically non-opioid analgesics, immediate-release opioids, or other formulations designated as first-line in the plan's policy. If that documented trial history is absent from the claim submission, the coverage is denied until step requirements are satisfied.
## Why This Denial Is Appealable
If the patient has already tried and failed the required prior-step therapies, the denial is based on missing documentation rather than clinical reality — and that documentation can be submitted on appeal. Additionally, most states and many federal guidelines recognize step-therapy override rights when a prior-step therapy is contraindicated, would cause clinical harm, or when the prescriber determines the patient is stable on the current therapy and a switch would be medically unsafe. Federal law (21st Century Cures Act provisions incorporated into ACA plans) provides specific step-therapy override protections.
## Federal Appeal Framework
- Step-therapy exception / internal appeal: File within the deadline on your denial notice. The 21st Century Cures Act requires ACA-compliant plans to have an exception process for step therapy; ERISA plans must provide a full-and-fair review under §503.
- Expedited review: Request within 72 hours if the step-therapy delay creates urgent clinical risk.
- External review (ACA §2719): After internal exhaustion, file for independent external review within approximately four months of the final denial.
## Appeal Process and Timeline
1. Obtain UHC's step-therapy protocol for extended-release opioids — identifying exactly which prior-step agents are required and for what duration or outcome threshold. 2. Gather chart records showing prior-step therapies already tried: agent names, start and stop dates, prescriber notes on outcomes and reasons for discontinuation. 3. If prior steps have not been tried, have the prescriber document whether each is contraindicated or otherwise clinically inappropriate for this patient, and explain why skipping directly to the prescribed agent is medically necessary. 4. Submit an internal appeal with the prescriber's step-therapy override letter and supporting chart documentation. 5. Escalate to external review if denied.
## Documentation to Gather
- Step-therapy trial history: For each required prior-step agent — agent name, dates, clinical outcome, reason for discontinuation (from the chart).
- Step-therapy exception grounds: Prescriber letter documenting contraindication, adverse response, clinical instability risk, or other recognized override basis.
- Diagnosis and severity documentation: Chart notes confirming the qualifying pain condition and its functional impact.
- FDA prescribing label: Confirming the target drug is approved for the relevant indication.
- Relevant guideline organization reference: Identifying the pain-medicine or specialty-society guideline that supports skipping or completing the step sequence.
## Criteria-Mapping Structure
Copy each step-therapy criterion from UHC's published policy into your appeal letter. Under each criterion, document the specific chart evidence: date, provider, clinical finding, and outcome. For override criteria, pair each override ground with the prescriber's specific statement and the supporting chart note. This structure ensures the reviewer can evaluate every requirement without having to search unorganized records.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →